- Home
- TOVX vs BX Comparison
TOVX vs BX Comparison
Compare TOVX & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOVX | BX |
|---|---|---|
| Founded | 2001 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 116.4B |
| IPO Year | 2012 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TOVX | BX |
|---|---|---|
| Price | $0.19 | $109.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 16 |
| Target Price | N/A | ★ $169.50 |
| AVG Volume (30 Days) | 6.5M | ★ 9.0M |
| Earning Date | 03-12-2026 | 04-16-2026 |
| Dividend Yield | N/A | ★ 4.18% |
| EPS Growth | ★ 89.07 | 6.91 |
| EPS | N/A | ★ 3.87 |
| Revenue | N/A | ★ $14,450,265,000.00 |
| Revenue This Year | N/A | $14.56 |
| Revenue Next Year | N/A | $21.82 |
| P/E Ratio | ★ N/A | $29.32 |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $0.16 | $101.73 |
| 52 Week High | $1.50 | $190.09 |
Technical Indicators
Market Signals| Indicator | TOVX | BX |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 40.79 |
| Support Level | $0.17 | $103.41 |
| Resistance Level | $0.26 | $165.14 |
| Average True Range (ATR) | 0.01 | 4.27 |
| MACD | 0.00 | 1.41 |
| Stochastic Oscillator | 37.45 | 57.91 |
Price Performance
Historical ComparisonAbout TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About BX Blackstone Inc.
Blackstone is the world's largest alternative-asset manager with $1.242 trillion in total asset under management, including $906.2 billion in fee-earning assets under management, at the end of September 2025. The company operates with scale in each of its major product lines: private equity (26% of fee-earning AUM and 33% of base management fees), real estate/real assets (31% and 35%), private credit (34% and 25%), and other alternatives (9% and 7%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).